Research programme: liposomal cytotoxic compounds - TOT Biopharm

Drug Profile

Research programme: liposomal cytotoxic compounds - TOT Biopharm

Alternative Names: TLD 208; TOT 201; TOT 202; TOT 203

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TOT Biopharm
  • Class Antineoplastics
  • Mechanism of Action Cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 25 Oct 2016 Preclinical trials in Cancer in China (unspecified route) (TOT Biopharm pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in China
  • 16 Jul 2016 No recent reports of development identified for research development in Colorectal-cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top